Fusion Antibodies (LON:FAB) Shares Down 20% – Should You Sell?

Fusion Antibodies plc (LON:FAB) shares fell 20% during trading on Tuesday. The stock traded as low as GBX 4 and last traded at GBX 4. Approximately 1,953,875 shares traded hands during mid-day trading, an increase of 322% from the average daily volume of 462,495 shares. The stock had previously closed at GBX 5.

Fusion Antibodies Stock Down 20.0%

The company has a current ratio of 2.82, a quick ratio of 2.36 and a debt-to-equity ratio of 20.41. The stock has a 50 day simple moving average of GBX 9.23 and a 200 day simple moving average of GBX 11.72. The firm has a market capitalization of £5.01 million, a PE ratio of -4.00 and a beta of 1.24.

Fusion Antibodies (LON:FAB) last issued its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. As a group, sell-side analysts forecast that Fusion Antibodies plc will post -130.00 earnings per share for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.